PRIMARY STUDY

Amyotrophic Lateral Sclerosis, the Endocannabinoid System, and Exogenous Cannabinoids: Current State and Clinical Implications

Key Findings:  The authors conclude that by harnessing the homeostatic regulatory powers of the ECS, this patient population may benefit from various cannabis-based therapeutics to mitigate diverse symptom expressions and improve QOL. Beneficial compound includes Cannabinoids and their acid forms: THC, THCA, CBD, CBDA, and CBG. Terpenes: β-Caryophyllene, α-Pinene, d-Limonene, Linalool, and the flavonoids Cannaflavin A/B.